Share

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Huda Suliman of Icaria Life Sciences discussed her company’s role in the rejuvenation biotechnology ecosystem, including small molecule drug discovery and drug screening along with how her company deals with irreproducibility in the scientific literature. She explained how species differences are an issue, and she explained the differences between aging-focused and traditional medical research.

News

More News

Even More News

About the author
mm

Josh Conway

Josh is a professional editor and is responsible for editing our articles before they become available to the public as well as moderating our Discord server. He is also a programmer, long-time supporter of rejuvenation biotechnology, and avid player of the strange game called "real life." Living in the center of the northern prairie, Josh enjoys long bike rides before the blizzards hit.
Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD